CRISPR Therapeutics AG (CRSP) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025)

$3.5M

Net Income/Loss (FY2025)

-$581.6M

Total Assets (FY2025)

$2.3B

Total Equity (FY2025)

$1.9B

Cash Flows from Operating Activities (FY2025)

-$345.0M

Source: CRISPR Therapeutics AG 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.